BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 33314398)

  • 21. Harnessing the cross-talk between tumor cells and tumor-associated macrophages with a nano-drug for modulation of glioblastoma immune microenvironment.
    Li TF; Li K; Wang C; Liu X; Wen Y; Xu YH; Zhang Q; Zhao QY; Shao M; Li YZ; Han M; Komatsu N; Zhao L; Chen X
    J Control Release; 2017 Dec; 268():128-146. PubMed ID: 29051064
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The N
    Zhao R; Li B; Zhang S; He Z; Pan Z; Guo Q; Qiu W; Qi Y; Zhao S; Wang S; Chen Z; Zhang P; Guo X; Xue H; Li G
    Front Immunol; 2021; 12():653711. PubMed ID: 34354698
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunophenotyping of Newly Diagnosed and Recurrent Glioblastoma Defines Distinct Immune Exhaustion Profiles in Peripheral and Tumor-infiltrating Lymphocytes.
    Mohme M; Schliffke S; Maire CL; Rünger A; Glau L; Mende KC; Matschke J; Gehbauer C; Akyüz N; Zapf S; Holz M; Schaper M; Martens T; Schmidt NO; Peine S; Westphal M; Binder M; Tolosa E; Lamszus K
    Clin Cancer Res; 2018 Sep; 24(17):4187-4200. PubMed ID: 29444930
    [No Abstract]   [Full Text] [Related]  

  • 24. Analysis of immunobiologic markers in primary and recurrent glioblastoma.
    Rahman M; Kresak J; Yang C; Huang J; Hiser W; Kubilis P; Mitchell D
    J Neurooncol; 2018 Apr; 137(2):249-257. PubMed ID: 29302887
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Higher cytolytic score correlates with an immunosuppressive tumor microenvironment and reduced survival in glioblastoma.
    Haddad AF; Chen JS; Oh T; Pereira MP; Joshi RS; Aghi MK
    Sci Rep; 2020 Oct; 10(1):17580. PubMed ID: 33067480
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Systemic Inflammation Associates With a Myeloid Inflamed Tumor Microenvironment in Primary Resected Colon Cancer-May Cold Tumors Simply Be Too Hot?
    Køstner AH; Nielsen PS; Georgsen JB; Parner ET; Nielsen MB; Kersten C; Steiniche T
    Front Immunol; 2021; 12():716342. PubMed ID: 34531864
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Explicating the Pivotal Pathogenic, Diagnostic, and Therapeutic Biomarker Potentials of Myeloid-Derived Suppressor Cells in Glioblastoma.
    Richard SA
    Dis Markers; 2020; 2020():8844313. PubMed ID: 33204365
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Potential role of tumor-infiltrating T-, B-lymphocytes, tumor-associated macrophages and IgA-secreting plasma cells in long-term survival in the rectal adenocarcinoma patients.
    Zinovkin DA; Kose SY; Nadyrov EA; Achinovich SL; Los' DM; Gavrilenko TE; Gavrilenko DI; Yuzugulen J; Pranjol MZI
    Life Sci; 2021 Dec; 286():120052. PubMed ID: 34656554
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immune landscapes associated with different glioblastoma molecular subtypes.
    Martinez-Lage M; Lynch TM; Bi Y; Cocito C; Way GP; Pal S; Haller J; Yan RE; Ziober A; Nguyen A; Kandpal M; O'Rourke DM; Greenfield JP; Greene CS; Davuluri RV; Dahmane N
    Acta Neuropathol Commun; 2019 Nov; 7(1):203. PubMed ID: 31815646
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Distribution pattern of tumor infiltrating lymphocytes and tumor microenvironment composition as prognostic indicators in anorectal malignant melanoma.
    Kim SW; Kim YI; Mustafa B; Kim MJ; Jeong G; Ahn SM; Lim SB; Yu CS; Kim JC; Hong SM; Park IJ
    Mod Pathol; 2021 Jan; 34(1):141-160. PubMed ID: 32709987
    [TBL] [Abstract][Full Text] [Related]  

  • 31. T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma.
    Woroniecka K; Chongsathidkiet P; Rhodin K; Kemeny H; Dechant C; Farber SH; Elsamadicy AA; Cui X; Koyama S; Jackson C; Hansen LJ; Johanns TM; Sanchez-Perez L; Chandramohan V; Yu YA; Bigner DD; Giles A; Healy P; Dranoff G; Weinhold KJ; Dunn GP; Fecci PE
    Clin Cancer Res; 2018 Sep; 24(17):4175-4186. PubMed ID: 29437767
    [No Abstract]   [Full Text] [Related]  

  • 32. Folate Receptor Beta Designates Immunosuppressive Tumor-Associated Myeloid Cells That Can Be Reprogrammed with Folate-Targeted Drugs.
    Cresswell GM; Wang B; Kischuk EM; Broman MM; Alfar RA; Vickman RE; Dimitrov DS; Kularatne SA; Sundaram CP; Singhal S; Eruslanov EB; Crist SA; Elzey BD; Ratliff TL; Low PS
    Cancer Res; 2021 Feb; 81(3):671-684. PubMed ID: 33203700
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tumor associated CD70 expression is involved in promoting tumor migration and macrophage infiltration in GBM.
    Ge H; Mu L; Jin L; Yang C; Chang YE; Long Y; DeLeon G; Deleyrolle L; Mitchell DA; Kubilis PS; Lu D; Qi J; Gu Y; Lin Z; Huang J
    Int J Cancer; 2017 Oct; 141(7):1434-1444. PubMed ID: 28612394
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immune microenvironment of experimental rat C6 gliomas resembles human glioblastomas.
    Gieryng A; Pszczolkowska D; Bocian K; Dabrowski M; Rajan WD; Kloss M; Mieczkowski J; Kaminska B
    Sci Rep; 2017 Dec; 7(1):17556. PubMed ID: 29242629
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Global immune fingerprinting in glioblastoma patient peripheral blood reveals immune-suppression signatures associated with prognosis.
    Alban TJ; Alvarado AG; Sorensen MD; Bayik D; Volovetz J; Serbinowski E; Mulkearns-Hubert EE; Sinyuk M; Hale JS; Onzi GR; McGraw M; Huang P; Grabowski MM; Wathen CA; Ahluwalia MS; Radivoyevitch T; Kornblum HI; Kristensen BW; Vogelbaum MA; Lathia JD
    JCI Insight; 2018 Nov; 3(21):. PubMed ID: 30385717
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Microglia promote glioblastoma via mTOR-mediated immunosuppression of the tumour microenvironment.
    Dumas AA; Pomella N; Rosser G; Guglielmi L; Vinel C; Millner TO; Rees J; Aley N; Sheer D; Wei J; Marisetty A; Heimberger AB; Bowman RL; Brandner S; Joyce JA; Marino S
    EMBO J; 2020 Aug; 39(15):e103790. PubMed ID: 32567735
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analysis of Spatial Organization of Suppressive Myeloid Cells and Effector T Cells in Colorectal Cancer-A Potential Tool for Discovering Prognostic Biomarkers in Clinical Research.
    Zwing N; Failmezger H; Ooi CH; Hibar DP; Cañamero M; Gomes B; Gaire F; Korski K
    Front Immunol; 2020; 11():550250. PubMed ID: 33193316
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of tumor immune environment between newly diagnosed and recurrent glioblastoma including matched patients.
    Wang F; Cathcart SJ; DiMaio DJ; Zhao N; Chen J; Aizenberg MR; Shonka NA; Lin C; Zhang C
    J Neurooncol; 2022 Aug; 159(1):163-175. PubMed ID: 35754074
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immune Cell Composition in Human Non-small Cell Lung Cancer.
    Stankovic B; Bjørhovde HAK; Skarshaug R; Aamodt H; Frafjord A; Müller E; Hammarström C; Beraki K; Bækkevold ES; Woldbæk PR; Helland Å; Brustugun OT; Øynebråten I; Corthay A
    Front Immunol; 2018; 9():3101. PubMed ID: 30774636
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Glioblastoma-Infiltrating CD8+ T Cells Are Predominantly a Clonally Expanded GZMK+ Effector Population.
    Wang AZ; Mashimo BL; Schaettler MO; Sherpa ND; Leavitt LA; Livingstone AJ; Khan SM; Li M; Anzaldua-Campos MI; Bradley JD; Leuthardt EC; Kim AH; Dowling JL; Chicoine MR; Jones PS; Choi BD; Cahill DP; Carter BS; Petti AA; Johanns TM; Dunn GP
    Cancer Discov; 2024 Jun; 14(6):1106-1131. PubMed ID: 38416133
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.